MeiraGTx Holdings plc
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following…
Biotechnology
US, New York [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about MeiraGTx Holdings plc's gradings, price targets and earnings estimates. None
FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
E | E | E | E | E | E | |||||||
2019 | -4.3700 | -2.027 | 0 | 6 | -82 | -114 | -78 | -6 | -80 | -6 | 44 | 16 |
2020 | -1.5800 | -1.581 | 13 | 17 | -52 | -89 | -51 | -17 | -58 | -17 | 46 | 44 |
2021 | -1.4300 | -2.060 | 15 | 22 | -53 | -116 | -53 | -22 | -62 | -22 | 44 | 58 |
2022 | -1.6300 | -2.687 | 37 | 32 | -71 | -151 | -71 | -32 | -81 | -32 | 43 | 90 |
2023 | -3.1600 | -1.682 | 15 | 40 | -142 | -84 | -115 | -40 | -125 | -40 | 46 | 111 |
2024 | -1.4900 | -1.822 | 14 | 31 | -84 | -102 | -57 | -31 | -137 | -31 | 47 | 87 |
2025 | - | 0.702 | - | 205 | - | 88 | - | -205 | - | -205 | - | 566 |
2026 | - | 2.F7X/td> | - | 2.F7X/td> | - | 2.F7X/td> | - | 2.F71/td> | - | 2.F71 | - | 2.F71 |
2027 | - | 1.F8X/td> | - | 1.F8X/td> | - | 1.F8X/td> | - | 1.F81/td> | - | 1.F81 | - | 1.F81 |
2028 | - | 0.F9X/td> | - | 0.F9X/td> | - | 0.F9X/td> | - | 0.F91/td> | - | 0.F91 | - | 0.F91 |